SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma’s subsidiary receives approval for registration of Risperidone Tablets

17 May 2011 Evaluate

Aurobindo Pharma’s wholly owned subsidiary - Aurobindo Pharma Australia Pty - has received approvals from Therapeutic Goods Administration (TGA), Government of Australia for registration of Risperidone Tablets 0.5mg, 1mg,2mg, 3mg, 4mg and Oral Solution 1mg/1ml and Alendronate Tablets 70mg.

Risperidone Tablets and Oral Solution are indicated in the treatment schizophrenia and falls under the neurological (CNS) segment. Alendronate Tablets 70mg are indicated for the treatment and prevention of osteoporosis.

Risperdione products have market size of approximately $27.5 million and Alendronate has $14million for twelve months ending September 2010 according to IMS. The company now has 8 approvals from TGA, Australia.

The company has registered growth of 12.51% in its net profit for the current year, 2011 at Rs 593.80 crore as compared to Rs 527.76 crore for the previous year. Its total income has increased by 26.44% at Rs 4141.11 crore for the year under review from Rs 3275.08 crore in previous year.

On consolidated basis, the group’s net profit for the year has increased marginally by 0.01% at Rs 563.45 crore as compared to Rs 563.40 crore for the previous year. Total income for the year has increased by 21.92% at 4406.67 crore as compared to Rs 3614.37 crore for the previous year

Aurobindo Pharma is the market leader in semi-synthetic penicillin drugs. It has presence in key therapeutic segments like SSPs, cephalosporins, anti-retrovirals, CNS, cardio-vascular, gastroenterology, etc 

Aurobindo Pharma Share Price

1491.35 7.95 (0.54%)
07-May-2026 12:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.80
Dr. Reddys Lab 1309.95
Cipla 1374.15
Zydus Lifesciences 941.40
Lupin 2469.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×